Here are five highlights:
1. The PentOS OI Putty is the first product of a new family of bone graft substitutes that have a proven ability to form bone.
2. PentOS OI Putty will be available to oral and maxillofacial surgery customers and will be joined by three additional PentOS OI products that are expected to launch in the coming months:
- PentOS OI Flex
- PentOS OI Sponge
- PentOS OI Fill
3. PentOS OI Putty is a de-mineralized bone matrix made from 100 percent human bone and does not contain any extrinsic carriers.
4. PentOS OI Putty will be offered in the Canadian market through the company’s direct sales and globally via the company’s network of distribution partners.
5. Antibe Therapeutics is a pharmaceutical company based in Toronto, Canada, that develops inflammation-reducing drugs based on gaseous mediator technology.
More articles on devices and implants:
Baird rates Exactech as ‘outperform’: 4 insights
VerteCore finishes 1st week of Lift device crowdfunding: 3 points
Orthofix shares reach new 1-year high: 3 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.